1 / 26

Europe Infectious Disease Diagnostics Market

The Europe infectious disease diagnostics market was valued at $1,394.3 million in 2020 and is expected to reach $7,900.4 million by 2031, witnessing a CAGR of 16.48% during the forecast period 2021-2031.

bisreports
Download Presentation

Europe Infectious Disease Diagnostics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 8/\ Europe Infectious Disease Diagnostics Market – Country-Wise Analysis Table of Content https://www.freepik.com/premium-photo/close-up-view-96-well-plate-used-biology- research_2652534.htm#page=1&query=96%20well%20plate&position=21&from_view=keyword Europe Infectious Disease Diagnostics Market Focus on Product, Testing Location, Infectious Disease Type, Infection Type, Technology, and End User Analysis and Forecast: 2021-2031 April 2022 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Europe Infectious Disease Diagnostics Market Copyright © 2022 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered, whether for sale or otherwise, to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary .......................................................................... 28 Research Methodology ..................................................................... 36 Scope of the Study ........................................................................... 41 1.Markets ..................................................................................... 44 1.1 Product Definition ............................................................................................ 45 1.1.1Definitions .................................................................................................... 45 1.1.2Inclusion and Exclusion ............................................................................. 46 1.2 Market Overview .............................................................................................. 46 1.3 Significant Technologies in Infectious Disease Diagnostics ....................... 47 1.4 Classification of Infectious Disease Diagnostics ......................................... 48 1.5 Europe Footprint .............................................................................................. 49 1.6 Market Dynamics ............................................................................................. 50 1.6.1Impact Analysis ........................................................................................... 50 1.6.2Market Drivers ............................................................................................. 51 1.6.2.1 Increasing Prevalence of Infectious Diseases ................................................... 51 1.6.2.2 Technological Innovation Resulting in Market Pull ............................................ 52 1.6.2.3 Significant External Funding Supporting Market Growth ................................... 53 1.6.3Market Restraints ........................................................................................ 54 Europe Infectious Disease Diagnostics Market 1.6.3.1 Uncertain Reimbursement Scenario .................................................................. 54 1.6.3.2 Lack of High Complexity Testing Centers .......................................................... 54 1.6.3.3 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests ................................................................................................ 55 1.6.4Market Opportunities .................................................................................. 55 1.6.4.1 Massive Scope for Adoption of Infectious Disease Diagnostics in Emerging Nations ............................................................................................................... 55 1.6.4.2 Technological Advancements in Molecular Techniques and Infectious Diagnostic Tests ................................................................................................ 56 3 All rights reserved at BIS Research Inc.

  4. 1.7 COVID-19 Impact on Europe Infectious Disease Diagnostics Market ......... 57 1.7.1COVID-19 Impact on Infectious Disease Diagnostics Market Size .......... 58 1.7.2Realistic Growth Scenario .......................................................................... 59 1.7.3Optimistic Growth Scenario ....................................................................... 59 1.7.4Disruption in Europe Infectious Disease Diagnostics Market Due to COVID-19 ................................................................................................... 60 1.8 Competitive Landscape................................................................................... 61 1.8.1Acquisitions ................................................................................................. 62 1.8.2Synergistic Activities .................................................................................. 62 1.8.3Product Launches and Approvals ............................................................. 63 1.8.4Business Expansion Activities .................................................................. 64 1.8.5Market-Share Analysis (by Company) ....................................................... 64 1.8.6Growth-Share Analysis (by Technology) .................................................. 66 1.9 Industry Insights .............................................................................................. 67 1.9.1Legal Requirements and Framework in Europe ....................................... 67 2.Products .................................................................................... 69 2.1 Overview ........................................................................................................... 70 2.1.1System .......................................................................................................... 71 2.1.2Kits and Reagents ....................................................................................... 72 Europe Infectious Disease Diagnostics Market 2.1.3Software ....................................................................................................... 74 3.Testing Location ........................................................................ 77 3.1 Overview ........................................................................................................... 78 3.1.1Laboratory Testing ...................................................................................... 79 3.1.2Point-of-Care Testing .................................................................................. 80 4. Technology ............................................................................... 82 4.1 Overview ........................................................................................................... 83 4.1.1Polymerase Chain Reaction (PCR) ............................................................ 84 4 All rights reserved at BIS Research Inc.

  5. 4.1.1.1 Real-Time PCR (RT-PCR) ................................................................................. 86 4.1.1.2 Digital PCR (d-PCR) .......................................................................................... 87 4.1.2Next-Generation Sequencing ..................................................................... 88 4.1.3Isothermal Nucleic Acid Amplification Technology (INAAT) ................... 89 4.1.4Microarray .................................................................................................... 91 4.1.5In-Situ Hybridization (ISH) .......................................................................... 92 4.1.6Immunodiagnostics ..................................................................................... 93 4.1.7Other Technologies ..................................................................................... 93 5.Infectious Disease Type ............................................................ 95 5.1 Overview ........................................................................................................... 96 5.1.1Bacterial Infectious Diseases ..................................................................... 97 5.1.2Viral Infectious Diseases ............................................................................ 98 5.1.3Fungal Infectious Diseases ........................................................................ 99 5.1.4Other Infectious Diseases ........................................................................ 100 6.Infection Type .......................................................................... 101 6.1 Overview ......................................................................................................... 102 6.1.1Respiratory Infections ............................................................................... 103 6.1.1.1 COVID-19 Infection .......................................................................................... 104 6.1.1.2 Influenza A and B ............................................................................................ 105 Europe Infectious Disease Diagnostics Market 6.1.1.3 Respiratory Syncytial Virus .............................................................................. 106 6.1.1.4 Mycoplasma Infections .................................................................................... 107 6.1.1.5 Pertussis Infections .......................................................................................... 107 6.1.1.6 Other Respiratory Infections ............................................................................ 108 6.1.2Hospital-Acquired Infections (HAIs) ........................................................ 109 6.1.3Sexually Transmitted Infections (STIs) .................................................... 109 6.1.3.1 Hepatitis B ....................................................................................................... 110 6.1.3.2 HIV-AIDS ......................................................................................................... 111 6.1.3.3 Human Papillomavirus (HPV) .......................................................................... 112 5 All rights reserved at BIS Research Inc.

  6. 6.1.3.4 Neisseria Gonorrhea ........................................................................................ 112 6.1.3.5 Other STIs ....................................................................................................... 113 6.1.4Other Infections ......................................................................................... 114 7.End User .................................................................................. 115 7.1 Overview ......................................................................................................... 116 7.1.1Hospitals .................................................................................................... 117 7.1.1.1 Hospitals (by Respiratory Infections) ............................................................... 118 7.1.1.1.1Hospitals (Influenza A and B) ................................................................................ 119 7.1.1.1.2Hospitals (COVID-19 Infection) .............................................................................. 119 7.1.1.1.3Hospitals (Respiratory Syncytial Virus (RSV)) ....................................................... 120 7.1.1.1.4Hospitals (Mycoplasma Infections) ........................................................................ 121 7.1.1.1.5Hospitals (Pertussis Infections) .............................................................................. 121 7.1.1.1.6Hospitals (Other Respiratory Infections) ................................................................ 122 7.1.1.2 Hospitals (by Sexually Transmitted Infections (STIs)) ..................................... 122 7.1.1.2.1Hospitals (Hepatitis B) ........................................................................................... 123 7.1.1.2.2Hospitals (HIV-AIDS) ............................................................................................. 123 7.1.1.2.3Hospitals (HPV)...................................................................................................... 124 7.1.1.2.4Hospitals (Neisseria Gonorrhea) ............................................................................ 124 7.1.1.2.5Hospitals (Other STIs) ........................................................................................... 125 7.1.2Diagnostic Centers .................................................................................... 125 7.1.2.1 Diagnostic Centers (by Respiratory Infections) ............................................... 126 Europe Infectious Disease Diagnostics Market 7.1.2.1.1Diagnostic Centers (Influenza A and B) ................................................................. 127 7.1.2.1.2Diagnostic Centers (COVID-19 Infection) .............................................................. 127 7.1.2.1.3Diagnostic Centers (Respiratory Syncytial Virus (RSV)) ....................................... 128 7.1.2.1.4Diagnostic Centers (Mycoplasma Infections) ........................................................ 128 7.1.2.1.5Diagnostic Centers (Pertussis Infections) .............................................................. 129 7.1.2.1.6Diagnostic Centers (Other Respiratory Infections) ................................................ 129 7.1.2.2 Diagnostic Centers (by Sexually Transmitted Infections (STIs)) ..................... 130 7.1.2.2.1Diagnostic Centers (Hepatitis B) ............................................................................ 131 7.1.2.2.2Diagnostic Centers (HIV-AIDS) .............................................................................. 131 6 All rights reserved at BIS Research Inc.

  7. 7.1.2.2.3Diagnostic Centers (HPV) ...................................................................................... 132 7.1.2.2.4Diagnostic Centers (Neisseria Gonorrhea) ............................................................ 132 7.1.2.2.5Diagnostic Centers (Other STIs) ............................................................................ 133 7.1.3Out-Patient Clinics/General Practitioners ............................................... 133 7.1.3.1 Out-Patient Clinics/General Practitioners (by Respiratory Infections) ............. 134 7.1.3.1.1Out-Patient Clinics/General Practitioners (Influenza A and B) .............................. 135 7.1.3.1.2Out-Patient Clinics/General Practitioners (COVID-19 Infection) ........................... 135 7.1.3.1.3Out-Patient Clinics/General Practitioners (Respiratory Syncytial Virus (RSV)) ............................................................................................................................... 136 7.1.3.1.4Out-Patient Clinics/General Practitioners (Mycoplasma Infections) ...................... 136 7.1.3.1.5Out-Patient Clinics/General Practitioners (Pertussis Infections) ........................... 137 7.1.3.1.6Out-Patient Clinics/General Practitioners (Other Respiratory Infections) .............. 137 7.1.3.2 Out-Patient Clinics/General Practitioners (by Sexually Transmitted Infections (STIs)) ............................................................................................. 138 7.1.3.2.1Out-Patient Clinics/General Practitioners (Hepatitis B) ......................................... 138 7.1.3.2.2Out-Patient Clinics/General Practitioners (HIV-AIDS) ........................................... 139 7.1.3.2.3Out-Patient Clinics/General Practitioners (HPV) ................................................... 139 7.1.3.2.4Out-Patient Clinics/General Practitioners (Neisseria Gonorrhea) ......................... 140 7.1.3.2.5Out-Patient Clinics/General Practitioners (Other STIs) ......................................... 140 7.1.4Research Laboratories .............................................................................. 141 7.1.4.1 Research Laboratories (by Respiratory Infections) ......................................... 142 7.1.4.1.1Research Laboratories (Influenza A and B) ........................................................... 142 Europe Infectious Disease Diagnostics Market 7.1.4.1.2Research Laboratories (COVID-19 Infection) ........................................................ 143 7.1.4.1.3Research Laboratories (Respiratory Syncytial Virus (RSV)) ................................. 143 7.1.4.1.4Research Laboratories (Mycoplasma Infections) .................................................. 144 7.1.4.1.5Research Laboratories (Pertussis Infections) ........................................................ 144 7.1.4.1.6Research Laboratories (Other Respiratory Infections) .......................................... 145 7.1.4.2 Research Laboratories (by Sexually Transmitted Infections (STIs)) ............... 145 7.1.4.2.1Research Laboratories (Hepatitis B) ...................................................................... 146 7.1.4.2.2Research Laboratories (HIV-AIDS)........................................................................ 146 7.1.4.2.3Research Laboratories (HPV) ................................................................................ 147 7 All rights reserved at BIS Research Inc.

  8. 7.1.4.2.4Research Laboratories (Neisseria Gonorrhea) ...................................................... 147 7.1.4.2.5Research Laboratories (Other STIs) ...................................................................... 148 7.1.5Other End Users ........................................................................................ 148 8. Regions................................................................................... 150 8.1 Overview ......................................................................................................... 151 8.2 Europe-5 ......................................................................................................... 153 8.2.1Europe Infectious Disease Diagnostics Market (by Infectious Disease Type) .......................................................................................... 155 8.2.2Germany ..................................................................................................... 156 8.2.3U.K. ............................................................................................................. 158 8.2.4France ......................................................................................................... 160 8.2.5Italy ............................................................................................................. 162 8.2.6Spain ........................................................................................................... 163 8.3 Baltic ............................................................................................................... 167 8.3.1Estonia ....................................................................................................... 169 8.3.2Lithuania .................................................................................................... 170 8.3.3Latvia .......................................................................................................... 171 8.4 Nordic ............................................................................................................. 171 8.4.1Denmark ..................................................................................................... 172 8.4.2Sweden ....................................................................................................... 173 Europe Infectious Disease Diagnostics Market 8.4.3Norway ....................................................................................................... 174 8.4.4Finland ........................................................................................................ 175 8.5 Rest-of- Europe .............................................................................................. 176 9.Company Profiles ..................................................................... 178 9.1 Overview ......................................................................................................... 179 9.2 Abbott ............................................................................................................. 180 9.2.1Company Overview ................................................................................... 180 8 All rights reserved at BIS Research Inc.

  9. 9.2.2Role of Abbott in the Europe Infectious Disease Diagnostics Market ...................................................................................................... 180 9.2.3Key Competitors of the Company ............................................................ 180 9.2.4Key Customers of the Company .............................................................. 180 9.2.5Corporate Strategies ................................................................................. 181 9.2.6Business Strategies .................................................................................. 181 9.2.7Financials ................................................................................................... 182 9.2.8Key Insights about the Financial Health of the Company ...................... 183 9.2.9SWOT Analysis .......................................................................................... 184 9.3 Agilent Technologies, Inc. ............................................................................ 185 9.3.1Company Overview ................................................................................... 185 9.3.2Role of Agilent Technologies, Inc. in the Europe Infectious Disease Diagnostics Market ................................................................................. 185 9.3.3Key Competitors of the Company ............................................................ 185 9.3.4Key Customers of the Company .............................................................. 185 9.3.5Corporate Strategies ................................................................................. 186 9.3.6Business Strategies .................................................................................. 186 9.3.7Financials ................................................................................................... 187 9.3.8Key Insights about the Financial of the Company .................................. 189 Europe Infectious Disease Diagnostics Market 9.3.9SWOT Analysis .......................................................................................... 190 9.4 Becton, Dickinson and Company (BD) ........................................................ 191 9.4.1Company Overview ................................................................................... 191 9.4.2Role of Becton, Dickinson and Company (BD) in the Europe Infectious Disease Diagnostics Market ................................................. 191 9.4.3Key Competitors of the Company ............................................................ 191 9.4.4Key Customers of the Company .............................................................. 191 9.4.5Corporate Strategies ................................................................................. 192 9.4.6Business Strategies .................................................................................. 192 9 All rights reserved at BIS Research Inc.

  10. 9.4.7Financials ................................................................................................... 193 9.4.8Key Insights about the Financial Health of the Company ...................... 195 9.4.9SWOT Analysis .......................................................................................... 196 9.5 bioMérieux SA ................................................................................................ 197 9.5.1Company Overview ................................................................................... 197 9.5.2Role of bioMérieux SA in the Europe Infectious Disease Diagnostics Market ...................................................................................................... 197 9.5.3Key Competitors of the Company ............................................................ 197 9.5.4Key Customers of the Company .............................................................. 197 9.5.5Business Strategies .................................................................................. 198 9.5.6Financials ................................................................................................... 199 9.5.7Key Insights about the Financial Health of the Company ...................... 200 9.5.8SWOT Analysis .......................................................................................... 201 9.6 Bio-Rad Laboratories, Inc. ............................................................................ 202 9.6.1Company Overview ................................................................................... 202 9.6.2Role of Bio-Rad Laboratories, Inc. in the Europe Infectious Disease Diagnostics Market ................................................................................. 202 9.6.3Key Competitors of the Company ............................................................ 202 9.6.4Key Customers of the Company .............................................................. 202 9.6.5Corporate Strategies ................................................................................. 203 Europe Infectious Disease Diagnostics Market 9.6.6Business Strategies .................................................................................. 203 9.6.7Financials ................................................................................................... 204 9.6.8Key Insights about the Financial Health of the Company ...................... 205 9.6.9SWOT Analysis .......................................................................................... 206 9.7 Danaher .......................................................................................................... 207 9.7.1Company Overview ................................................................................... 207 9.7.2Role of Danaher in the Europe Infectious Disease Diagnostics Market ...................................................................................................... 207 10 All rights reserved at BIS Research Inc.

  11. 9.7.3Key Competitors of the Company ............................................................ 207 9.7.4Key Customers of the Company .............................................................. 207 9.7.5Corporate Strategies ................................................................................. 208 9.7.6Business Strategies .................................................................................. 208 9.7.7Financials ................................................................................................... 209 9.7.8Key Insights about the Financial Health of the Company ...................... 211 9.7.9SWOT Analysis .......................................................................................... 212 9.8 F. Hoffmann-La Roche Ltd ............................................................................ 213 9.8.1Company Overview ................................................................................... 213 9.8.2Role of F. Hoffmann-La Roche Ltd in the Europe Infectious Disease Diagnostics Market ................................................................................. 213 9.8.3Key Competitors of the Company ............................................................ 213 9.8.4Key Customers of the Company .............................................................. 213 9.8.5Business Strategies .................................................................................. 214 9.8.6Financials ................................................................................................... 215 9.8.7Key Insights about the Financial Health of the Company ...................... 217 9.8.8SWOT Analysis .......................................................................................... 218 9.9 Illumina, Inc. ................................................................................................... 219 9.9.1Company Overview ................................................................................... 219 Europe Infectious Disease Diagnostics Market 9.9.2Role of Illumina, Inc. in the Europe Infectious Disease Diagnostics Market ...................................................................................................... 219 9.9.3Key Competitors of the Company ............................................................ 219 9.9.4Key Customers of the Company .............................................................. 219 9.9.5Financials ................................................................................................... 220 9.9.6Key Insights about the Financial Health of the Company ...................... 222 9.9.7SWOT Analysis .......................................................................................... 223 9.10QIAGEN N.V. ................................................................................................... 224 9.10.1Company Overview ................................................................................. 224 11 All rights reserved at BIS Research Inc.

  12. 9.10.2Role of QIAGEN N.V. in the Europe Infectious Disease Diagnostics Market ...................................................................................................... 224 9.10.3Key Competitors of the Company ......................................................... 224 9.10.4Key Customers of the Company ............................................................ 225 9.10.5Corporate Strategies ............................................................................... 225 9.10.6Business Strategies ................................................................................ 226 9.10.7Financials ................................................................................................ 226 9.10.8Key Insights about the Financial Health of the Company ................... 228 9.10.9SWOT Analysis ........................................................................................ 229 9.11Siemens Healthcare GmbH ........................................................................... 230 9.11.1Company Overview ................................................................................. 230 9.11.2Role of Siemens Healthcare GmbH in the Europe Infectious Disease Diagnostics Market ................................................................... 230 9.11.3Key Competitors of the Company ......................................................... 230 9.11.4Key Customers of the Company ............................................................ 230 9.11.5Business Strategies ................................................................................ 231 9.11.6Financials ................................................................................................ 231 9.11.7Key Insights about the Financial Health of the Company ................... 233 9.11.8SWOT Analysis ........................................................................................ 234 Europe Infectious Disease Diagnostics Market 9.12Thermo Fisher Scientific Inc. ........................................................................ 235 9.12.1Company Overview ................................................................................. 235 9.12.2Role of Thermo Fisher Scientific Inc. in the Europe Infectious Disease Diagnostics Market ................................................................... 235 9.12.3Key Competitors of the Company ......................................................... 235 9.12.4Key Customers of the Company ............................................................ 235 9.12.5Business Strategies ................................................................................ 236 9.12.6Financials ................................................................................................ 236 9.12.7Key Insights about the Financial Health of the Company ................... 238 12 All rights reserved at BIS Research Inc.

  13. 9.12.8SWOT Analysis ........................................................................................ 239 9.13PerkinElmer Inc. ............................................................................................. 240 9.13.1Company Overview ................................................................................. 240 9.13.2Role of PerkinElmer Inc. in the Europe Infectious Disease Diagnostics Market ................................................................................. 240 9.13.3Key Competitors of the Company ......................................................... 240 9.13.4Key Customers of the Company ............................................................ 241 9.13.5Financials ................................................................................................ 241 9.13.6Key Insights about the Financial Health of the Company ................... 243 9.13.7SWOT Analysis ........................................................................................ 244 9.14Hologic Inc. (Mobidiag Ltd.) .......................................................................... 245 9.14.1Company Overview ................................................................................. 245 9.14.2Role of Hologic Inc. (Mobidiag Ltd.) in the Europe Infectious Disease Diagnostics Market ................................................................... 245 9.14.3Key Competitors of the Company ......................................................... 245 9.14.4Key Customers of the Company ............................................................ 246 9.14.5Financials ................................................................................................ 246 9.14.6Key Insights about the Financial Health of the Company ................... 248 9.14.7SWOT Analysis ........................................................................................ 249 Emerging Companies ..................................................................... 250 Europe Infectious Disease Diagnostics Market 9.15Abacus Diagnostica Oy ................................................................................. 250 9.15.1Company Overview ................................................................................. 250 9.15.2Role of Abacus Diagnostica Oy in the Europe Infectious Disease Diagnostics Market ................................................................................. 250 9.15.3Key Competitors of the Company ......................................................... 250 9.15.4Key Customers of the Company ............................................................ 250 9.15.5Business Strategies ................................................................................ 251 9.15.6SWOT Analysis ........................................................................................ 252 13 All rights reserved at BIS Research Inc.

  14. 9.16Novacyt Group. .............................................................................................. 253 9.16.1Company Overview ................................................................................. 253 9.16.2Role of Novacyt Group. in the Europe Infectious Disease Diagnostics Market ................................................................................. 253 9.16.3Key Competitors of the Company ......................................................... 253 9.16.4Key Customers of the Company ............................................................ 253 9.16.5Business Strategies ................................................................................ 254 9.16.6Financials ................................................................................................ 254 9.16.7Key Insights about the Financial Health of the Company ................... 255 9.16.8SWOT Analysis ........................................................................................ 256 9.17Biocartis ......................................................................................................... 257 9.17.1Company Overview ................................................................................. 257 9.17.2Role of Biocartis in the Europe Infectious Disease Diagnostics Market ...................................................................................................... 257 9.17.3Key Competitors of the Company ......................................................... 257 9.17.4Key Customers of the Company ............................................................ 257 9.17.5Business Strategies ................................................................................ 258 9.17.6SWOT Analysis ........................................................................................ 259 Europe Infectious Disease Diagnostics Market 14 All rights reserved at BIS Research Inc.

  15. List of Figures Figure 1:Distribution of Chronic Lower Respiratory Diseases Figure 2:Europe Infectious Disease Diagnostics Market (Realistic and Optimistic Scenario), $Million, 2020-2031 Figure 3:Europe Infectious Disease Diagnostics Market Dynamics Figure 4:Share of Key Market Strategies and Developments, January 2018-March 2022 Figure 5:Europe Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 6:Europe Infectious Disease Diagnostics Market (by Product), $Million, 2020 Vs. 2031 Figure 7:Europe Infectious Disease Diagnostics Market (by Testing Location), $Million, 2020 Vs. 2031 Figure 8:Europe Infectious Disease Diagnostics Market (by Technology), $Million, 2020 Vs. 2031 Figure 9:Europe Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020 Vs. 2031 Figure 10:Europe Infectious Disease Diagnostics Market (by Infection Type), $Million, 2020 Vs. 2031 Figure 11:Europe Infectious Disease Diagnostics Market (by End User), $Million, 2020 Vs. 2031 Figure 12:Europe Infectious Disease Diagnostics Market: Research Methodology Figure 13:Bottom-Up Approach (Segment-Wise Analysis) Figure 14:Top-Down Approach (Segment-Wise Analysis) Figure 15:Europe Infectious Disease Diagnostics Market Segmentation Figure 16:Role of Infectious Disease Diagnostics in Healthcare Figure 17:Classification of Europe Infectious Disease Diagnostics Figure 18:Europe Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 19:Europe Infectious Disease Diagnostics Market Dynamics Figure 20:Distribution of Chronic Lower Respiratory Diseases Figure 21:Impact of COVID-19 on Europe Infectious Disease Diagnostics Market Figure 22:Europe Infectious Disease Diagnostics Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031 Figure 23:Europe Infectious Disease Diagnostics Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031 Figure 24:COVID-19 Impact Analysis of Europe Infectious Disease Diagnostics Market, 2019-2025 Figure 25:Share of Key Developments and Strategies, January 2018–March 2022 Figure 26:Share of Acquisitions (by Company), January 2018-March 2022 Figure 27:Share of Synergistic Activities (by Company), January 2018-March 2022 Figure 28:Share of Product Launches and Approvals (by Company), January 2018-March 2022 Figure 29:Share of Business Expansion Activities (by Company), January 2018-March 2022 Figure 30:Market-Share Analysis for Europe Infectious Disease Diagnostics Market, $Million, 2019 and 2020 Figure 31:Growth-Share Analysis of Europe Infectious Disease Diagnostics Market (by Technology), 2020-2031 Figure 32:Europe In-Vitro Diagnostic Devices Regulation Regulatory Process Europe Infectious Disease Diagnostics Market 15 All rights reserved at BIS Research Inc.

  16. Figure 33:Share of Europe Infectious Disease Diagnostics Market (by Product), $Million, 2020 and 2031 Figure 34:Europe Infectious Disease Diagnostics Market (System), $Million, 2020-2031 Figure 35:General Workflow of a Molecular Diagnostic Kit Figure 36:Europe Infectious Disease Diagnostics Market (Kits and Reagents), $Million, 2020-2031 Figure 37:Aspects of Software Development Figure 38:Europe Infectious Disease Diagnostics Market (Software), $Million, 2020-2031 Figure 39:Europe Infectious Disease Diagnostics Market (by Testing Location) Figure 40:Share of Europe Infectious Disease Diagnostics Market (by Testing Location), $Million, 2020 and 2031 Figure 41:Europe Infectious Disease Diagnostics Market (Laboratory Testing), $Million, 2020-2031 Figure 42:Europe Infectious Disease Diagnostics Market (Point-of-Care Testing), $Million, 2020-2031 Figure 43:Europe Infectious Disease Diagnostics Market (by Technology) Figure 44:Share of Europe Infectious Disease Diagnostics Market (by Technology), $Million, 2020 and 2031 Figure 45:Europe Infectious Disease Diagnostics Market (Polymerase Chain Reaction (PCR)), $Million, 2020-2031 Figure 46:Europe Infectious Disease Diagnostics Market (Real-Time PCR (RT-PCR), by Polymerase Chain Reaction (PCR)), $Million, 2020-2031 Figure 47:Europe Infectious Disease Diagnostics Market (Digital PCR (d-PCR), by Polymerase Chain Reaction (PCR)), $Million, 2020-2031 Figure 48:Europe Infectious Disease Diagnostics Market (Next-Generation Sequencing), $Million, 2020-2031 Figure 49:Europe Infectious Disease Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), $Million, 2020-2031 Figure 50:Europe Infectious Disease Diagnostics Market (Microarray), $Million, 2020-2031 Figure 51:Europe Infectious Disease Diagnostics Market (In-Situ Hybridization (ISH)), $Million, 2020- 2031 Figure 52:Europe Infectious Disease Diagnostics Market (Immunodiagnostics), $Million, 2020-2031 Figure 53:Europe Infectious Disease Diagnostics Market (Other Technologies), $Million, 2020-2031 Figure 54:Europe Infectious Disease Diagnostics Market (by Infectious Disease Type) Figure 55:Europe Infectious Disease Diagnostics Market (by Infectious Diseases Type), $Million, 2020 and 2031 Figure 56:Europe Infectious Disease Diagnostics Market (Bacterial Infectious Diseases), $Million, 2020-2031 Figure 57:Europe Infectious Disease Diagnostics Market (Viral Infectious Diseases), $Million, 2020- 2031 Figure 58:Europe Infectious Disease Diagnostics Market (Fungal Infectious Diseases), $Million, 2020- 2031 Figure 59:Europe Infectious Disease Diagnostics Market (Other Infectious Diseases), $Million, 2020- 2031 Figure 60:Europe Infectious Disease Diagnostics Market (by Infection Type) Figure 61:Europe Infectious Disease Diagnostics Market (by Infection Type), $Million, 2020 and 2031 Figure 62:Europe Infectious Disease Diagnostics Market (Respiratory Infections), $Million, 2020-2031 Europe Infectious Disease Diagnostics Market 16 All rights reserved at BIS Research Inc.

  17. Figure 63:Europe Infectious Disease Diagnostics Market (COVID-19 Infection, by Respiratory Infections), $Million, 2020-2031 Figure 64:Europe Infectious Disease Diagnostics Market (Influenza A and B, by Respiratory Infections), $Million, 2020-2031 Figure 65:Europe Infectious Disease Diagnostics Market (Respiratory Syncytial Virus, by Respiratory Infections), $Million, 2020-2031 Figure 66:Europe Infectious Disease Diagnostics Market (Mycoplasma Infections, by Respiratory Infections), $Million, 2020-2031 Figure 67:Europe Infectious Disease Diagnostics Market (Pertussis Infections, by Respiratory Infections), $Million, 2020-2031 Figure 68:Europe Infectious Disease Diagnostics Market (Other Respiratory Infections, by Respiratory Infections), $Million, 2020-2031 Figure 69:Europe Infectious Disease Diagnostics Market (Hospital-Acquired Infections (HAIs)), $Million, 2020-2031 Figure 70:Europe Infectious Disease Diagnostics Market (Sexually Transmitted Infections), $Million, 2020-2031 Figure 71:Europe Infectious Disease Diagnostics Market (Hepatitis B, by Sexually Transmitted Infections), $Million, 2020-2031 Figure 72:Europe Infectious Disease Diagnostics Market (HIV-AIDS, by Sexually Transmitted Infections), $Million, 2020-2031 Figure 73:Europe Infectious Disease Diagnostics Market (Human Papillomavirus (HPV), by Sexually Transmitted Infections), $Million, 2020-2031 Figure 74:Europe Infectious Disease Diagnostics Market (Neisseria Gonorrhea, by Sexually Transmitted Infections), $Million, 2020-2031 Figure 75:Europe Infectious Disease Diagnostics Market (Other STIs, by Sexually Transmitted Infections), $Million, 2020-2031 Figure 76:Europe Infectious Disease Diagnostics Market (Other Infections), $Million, 2020-2031 Figure 77:Europe Infectious Disease Diagnostics Market (by End User) Figure 78:Share of Europe Infectious Disease Diagnostics Market (by End User), $Million, 2020 and 2031 Figure 79:Europe Infectious Disease Diagnostics Market (Hospitals), $Million, 2020-2031 Figure 80:Europe Infectious Disease Diagnostics Market (Hospitals, by Respiratory Infections), $Million, 2020-2031 Figure 81:Europe Infectious Disease Diagnostics Market (Hospitals, Influenza A and B), $Million, 2020-2031 Figure 82:Europe Infectious Disease Diagnostics Market (Hospitals, COVID-19 Infection), $Million, 2020-2031 Figure 83:Europe Infectious Disease Diagnostics Market (Hospitals, Respiratory Syncytial Virus (RSV)), $Million, 2020-2031 Figure 84:Europe Infectious Disease Diagnostics Market (Hospitals, Mycoplasma Infections), $Million, 2020-2031 Figure 85:Europe Infectious Disease Diagnostics Market (Hospitals, Pertussis Infections), $Million, 2020-2031 Figure 86:Europe Infectious Disease Diagnostics Market (Hospitals, Other Respiratory Infections), $Million, 2020-2031 Figure 87:Europe Infectious Disease Diagnostics Market By (Hospitals, by Sexually Transmitted Infections), $Million, 2020-2031 Europe Infectious Disease Diagnostics Market 17 All rights reserved at BIS Research Inc.

  18. Figure 88:Europe Infectious Disease Diagnostics Market (Hospitals, Hepatitis B), $Million, 2020-2031 Figure 89:Europe Infectious Disease Diagnostics Market (Hospitals, HIV-AIDS), $Million, 2020-2031 Figure 90:Europe Infectious Disease Diagnostics Market (Hospitals, HPV), $Million, 2020-2031 Figure 91:Europe Infectious Disease Diagnostics Market (Hospitals, Neisseria Gonorrhea), $Million, 2020-2031 Figure 92:Europe Infectious Disease Diagnostics Market (Hospitals, Other STIs), $Million, 2020-2031 Figure 93:Europe Infectious Disease Diagnostics Market (Diagnostic Centers), $Million, 2020-2031 Figure 94:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, by Respiratory Infections) $Million, 2020-2031 Figure 95:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Influenza A and B), $Million, 2020-2031 Figure 96:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, COVID-19 Infection), $Million, 2020-2031 Figure 97:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Respiratory Syncytial Virus), $Million, 2020-2031 Figure 98:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Mycoplasma Infections), $Million, 2020-2031 Figure 99:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Pertussis Infections), $Million, 2020-2031 Figure 100:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Other Respiratory Infections), $Million, 2020-2031 Figure 101:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, by Sexually Transmitted Infections), $Million, 2020-2031 Figure 102:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Hepatitis B), $Million, 2020-2031 Figure 103:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, HIV-AIDS), $Million, 2020-2031 Figure 104:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, HPV), $Million, 2020- 2031 Figure 105:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Neisseria Gonorrhea), $Million, 2020-2031 Figure 106:Europe Infectious Disease Diagnostics Market (Diagnostic Centers, Other STIs), $Million, 2020-2031 Figure 107:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners), $Million, 2020-2031 Figure 108:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, by Respiratory Infections), $Million, 2020-2031 Figure 109:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Influenza A and B), $Million, 2020-2031 Figure 110:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, COVID-19 Infection), $Million, 2020-2031 Figure 111:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, by Respiratory Syncytial Virus (RSV)), $Million, 2020-2031 Figure 112:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Mycoplasma Infections), $Million, 2020-2031 Figure 113:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Pertussis Infections), $Million, 2020-2031 Europe Infectious Disease Diagnostics Market 18 All rights reserved at BIS Research Inc.

  19. Figure 114:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Other Respiratory Infections), $Million, 2020-2031 Figure 115:Europe Infectious Disease Diagnostics Market By (Out-Patient Clinics/General Practitioners, by Sexually Transmitted Infections), $Million, 2020-2031 Figure 116:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Hepatitis B), $Million, 2020-2031 Figure 117:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, HIV-AIDS), $Million, 2020-2031 Figure 118:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, HPV), $Million, 2020-2031 Figure 119:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Neisseria Gonorrhea), $Million, 2020-2031 Figure 120:Europe Infectious Disease Diagnostics Market (Out-Patient Clinics/General Practitioners, Other STIs), $Million, 2020-2031 Figure 121:Europe Infectious Disease Diagnostics Market (Research Laboratories), $Million, 2020- 2031 Figure 122:Europe Infectious Disease Diagnostics Market (Research Laboratories, by Respiratory Infections), Respiratory Infections, $Million, 2020-2031 Figure 123:Europe Infectious Disease Diagnostics Market (Research Laboratories, Influenza A and B), $Million, 2020-2031 Figure 124:Europe Infectious Disease Diagnostics Market (Research Laboratories COVID-19 Infection), $Million, 2020-2031 Figure 125:Europe Infectious Disease Diagnostics Market (Research Laboratories, Respiratory Syncytial Virus (RSV)), $Million, 2020-2031 Figure 126:Europe Infectious Disease Diagnostics Market (Research Laboratories, Mycoplasma Infections), $Million, 2020-2031 Figure 127:Europe Infectious Disease Diagnostics Market (Research Laboratories, Pertussis Infections), $Million, 2020-2031 Figure 128:Europe Infectious Disease Diagnostics Market (Research Laboratories, Other Respiratory Infections), $Million, 2020-2031 Figure 129:Europe Infectious Disease Diagnostics Market (Research Laboratories, Sexually Transmitted Infections), $Million, 2020-2031 Figure 130:Europe Infectious Disease Diagnostics Market (Research Laboratories, Hepatitis B), $Million, 2020-2031 Figure 131:Europe Infectious Disease Diagnostics Market (Research Laboratories, HIV-AIDS), $Million, 2020-2031 Figure 132:Europe Infectious Disease Diagnostics Market (Research Laboratories, HPV), $Million, 2020-2031 Figure 133:Europe Infectious Disease Diagnostics Market (Research Laboratories, Neisseria Gonorrhea), $Million, 2020-2031 Figure 134:Europe Infectious Disease Diagnostics Market (Research Laboratories, Other STIs), $Million, 2020-2031 Figure 135:Europe Infectious Disease Diagnostics Market (Other End Users), $Million, 2020-2031 Figure 136:Europe Infectious Disease Diagnostics Market (by Region), $Million, 2020-2031 Figure 137:Europe Infectious Disease Diagnostics Market (by Country), $Million, 2020 and 2031 Figure 138:Europe Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 139:Europe: Market Dynamics Europe Infectious Disease Diagnostics Market 19 All rights reserved at BIS Research Inc.

  20. Figure 140:Europe Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020 and 2031 Figure 141:Germany Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 142:Germany Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031 Figure 143:U.K. Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 144:U.K. Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020- 2031 Figure 145:France Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 146:France Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031 Figure 147:Italy Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 148:Italy Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020- 2031 Figure 149:Spain Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 150:Spain Infectious Disease Diagnostics Market (by Infectious Disease Type), $Million, 2020-2031 Figure 151:Baltic Infectious Disease Diagnostics Market (by Country), $Million, 2020 and 2031 Figure 152:Baltic Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 153:Baltic: Market Dynamics Figure 154:Estonia Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 155:Lithuania Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 156:Latvia Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 157:Nordic Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 158:Denmark Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 159:Sweden Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 160:Norway Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 161:Finland Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 162:Rest-of-Europe Infectious Disease Diagnostics Market, $Million, 2020-2031 Figure 163:Rest-of-Europe Infectious Disease Diagnostics Market, Thousand Unit, 2020-2031 Figure 164:Share of Key Companies Profiled Figure 165:Abbott: Product Portfolio Figure 166:Abbott: Overall Financials, $Million, 2019-2021 Figure 167:Abbott: Revenue (by Segment), $Million, 2019-2021 Figure 168:Abbott: Revenue (by Region), $Million, 2019-2021 Figure 169:Abbott: R&D Expenditure, $Million, 2019-2021 Figure 170:Abbott: SWOT Analysis Figure 171:Agilent Technologies, Inc.: Product Portfolio Figure 172:Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021 Figure 173:Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 174:Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 175:Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021 Europe Infectious Disease Diagnostics Market 20 All rights reserved at BIS Research Inc.

  21. Figure 176:Agilent Technologies, Inc.: SWOT Analysis Figure 177:Becton, Dickinson and Company (BD): Product Portfolio Figure 178:Becton, Dickinson and Company (BD): Overall Financials, $Million, 2019-2021 Figure 179:Becton, Dickinson and Company (BD): Revenue (by Segment), $Million, 2019-2021 Figure 180:Becton, Dickinson and Company (BD): Revenue (by Region), $Million, 2019-2021 Figure 181:Becton, Dickinson and Company (BD): R&D Expenditure, $Million, 2019-2021 Figure 182:Becton, Dickinson and Company: SWOT Analysis Figure 183:bioMérieux SA: Product Portfolio Figure 184:bioMérieux SA: Overall Financials, $Million, 2019-2021 Figure 185:bioMérieux SA: Revenue (by Segment), $Million, 2019-2021 Figure 186:bioMérieux SA: Revenue (by Region), $Million, 2019-2021 Figure 187:bioMérieux SA: R&D Expenditure, $Million, 2019-2021 Figure 188:bioMérieux SA: SWOT Analysis Figure 189:Bio-Rad Laboratories, Inc.: Product Portfolio Figure 190:Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021 Figure 191:Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 192:Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 193:Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 194:Bio-Rad Laboratories, Inc.: SWOT Analysis Figure 195:Danaher: Product Portfolio Figure 196:Danaher: Overall Financials, $Million, 2019-2021 Figure 197:Danaher: Revenue (by Segment), $Million, 2019-2021 Figure 198:Danaher: Revenue (by Region), $Million, 2019-2021 Figure 199:Danaher: R&D Expenditure, $Million, 2019-2021 Figure 200:Danaher: SWOT Analysis Figure 201:F. Hoffmann-La Roche Ltd: Product Portfolio Figure 202:F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021 Figure 203:F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021 Figure 204:F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2018-2020 Figure 205:F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021 Figure 206:F. Hoffmann-La Roche Ltd: SWOT Analysis Figure 207:Illumina, Inc.: Product Portfolio Figure 208:Illumina, Inc.: Overall Financials, $Million, 2019-2021 Figure 209:Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 210:Illumina, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 211:Illumina, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 212:Illumina, Inc.: SWOT Analysis Figure 213:QIAGEN N.V.: Product Portfolio Figure 214:QIAGEN N.V.: Overall Financials, $Million, 2018-2020 Figure 215:QIAGEN N.V.: Revenue (by Segment), $Million, 2018-2020 Europe Infectious Disease Diagnostics Market 21 All rights reserved at BIS Research Inc.

  22. Figure 216:QIAGEN N.V.: Revenue (by Region), $Million, 2018-2020 Figure 217:QIAGEN N.V.: R&D Expenditure, $Million, 2018-2020 Figure 218:QIAGEN N.V.: SWOT Analysis Figure 219:Siemens Healthcare GmbH: Product Portfolio Figure 220:Siemens Healthcare GmbH: Overall Financials, $Million, 2019-2021 Figure 221:Siemens Healthcare GmbH: Revenue (by Segment), $Million, 2019-2021 Figure 222:Siemens Healthcare GmbH: Revenue (by Region), $Million, 2019-2021 Figure 223:Siemens Healthcare GmbH: R&D Expenditure, $Million, 2019-2021 Figure 224:Siemens Healthcare GmbH: SWOT Analysis Figure 225:Thermo Fisher Scientific Inc.: Product Portfolio Figure 226:Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021 Figure 227:Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 228:Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021 Figure 229:Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021 Figure 230:Thermo Fisher Scientific Inc.: SWOT Analysis Figure 231:PerkinElmer Inc.: Product Portfolio Figure 232:PerkinElmer Inc.: Overall Financials, $Million, 2019-2021 Figure 233:PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 234:PerkinElmer, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 235:PerkinElmer, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 236:PerkinElmer, Inc.: SWOT Analysis Figure 237:Hologic Inc. (Mobidiag Ltd.): Product Portfolio Figure 238:Hologic Inc. (Mobidiag Ltd.): Overall Financials, $Million, 2019-2021 Figure 239:Hologic Inc. (Mobidiag Ltd.): Revenue (by Segment), $Million, 2019-2021 Figure 240:Hologic Inc. (Mobidiag Ltd.): Revenue (by Region), $Million, 2019-2021 Figure 241:Hologic Inc. (Mobidiag Ltd.): R&D Expenditure, $Million, 2019-2021 Figure 242:Hologic Inc. (Mobidiag Ltd.): SWOT Analysis Figure 243:Abacus Diagnostica Oy: Product Portfolio Figure 244:Abacus Diagnostica Oy: SWOT Analysis Figure 245:Novacyt Group.: Product Portfolio Figure 246:Novacyt Group.: Overall Financials, $Million, 2018-2020 Figure 247:Novacyt Group.: Revenue (by Segment), $Million, 2018-2020 Figure 248:Novacyt Group.: R&D Expenditure, $Million, 2018-2020 Figure 249:Novacyt Group.: SWOT Analysis Figure 250:Biocartis: Product Portfolio Figure 251:Biocartis: SWOT Analysis Europe Infectious Disease Diagnostics Market 22 All rights reserved at BIS Research Inc.

  23. List of Tables Table 1: Table 2: Table 3: Table 4: Table 5: Table 6: Table 7: Table 8: COVID-19 Impact on Europe Infectious Disease Diagnostics Market Products Launched by Various Manufacturers for Infectious Disease Diagnostics Research Companies Providing System Companies Providing Kits and Reagents Companies Providing Software PCR-Based Infectious Diagnostics Products NGS-Based Infectious Diagnostics Products Key Players Offering Infectious Diagnostics in the U.K. Europe Infectious Disease Diagnostics Market 23 All rights reserved at BIS Research Inc.

  24. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have the vision to be a leading and preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More Europe Infectious Disease Diagnostics Market Know More 24 All rights reserved at BIS Research Inc.

  25. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published, or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates, and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies. For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 Europe Infectious Disease Diagnostics Market 25 All rights reserved at BIS Research Inc.

  26. Europe Infectious Disease Diagnostics Market BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Europe Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 26 www.bisresearch.com All rights reserved at BIS Research Inc.

More Related